Opna Bio

Northpond Ventures

Longitude Capital

Menlo Ventures

Are you attending the AACR-NCI-EORTC International Conference in Boston next week? We’re looking forward to presenting preclinical data on Opna’s EP300/CBP bromodomain inhibitors, OPN-6602 and OPN-6742, in metastatic castration-resistant prostate cancer (mCRPC). 
Details: Sat, Oct 14th, Hynes Convention Center, Abstract #CO85, Poster Session C, Level 2, Exhibit Hall D, 12:30-4 pm ET #AACR-NCI-EORTC #prostatecancer #BETinhibition

Check out Opna’s emerging company profile in this week’s BioCentury, which details the company’s formation based on a novel discovery from Dr. Doug Hanahan’s lab at the Swiss Federal Institute of Lausanne revealing the fragile X mental retardation protein (FMRP) as a new cancer target. Armed additionally with five programs licensed from the former Plexxikon, including two clinical-stage compounds, Opna is advancing its robust pipeline in multiple cancer indications, including myelofibrosis and histiocytosis. https://lnkd.in/g6D9ye8Z (subscription req'd) #FMRP #oncology #Phase2

We are thrilled to announce our official debut as Opna Bio this morning, launching with a $38 million Series A financing from Longitude Capital, Northpond Ventures and Menlo Ventures. Opna is a rare kind of start-up, founded to advance a novel oncology discovery target (fragile X mental retardation protein, or FRMP) that plays a key role in helping tumors evade immune destruction, and strengthened with a portfolio of validated clinical and preclinical compounds acquired from Plexxikon, Inc. The company was cofounded by Gideon Bollag, PhD, CEO, Douglas Hanahan, PhD, and Joseph Schlessinger, PhD, who collectively have garnered multiple FDA-approved oncology drugs to their names.
https://lnkd.in/gGEydBWV

More about FMRP’s role in tumor immune evasion can be viewed in last week’s Science. https://lnkd.in/gWx_en5d
#FMRP #oncologypioneers #SeriesA #overcomingtumorimmunosuppression #addressinghallmarksofcancer

Metric
Company Name	Opna Bio
Symbol
MSH ID	COM:OPNABIO
Market	PRIVATE
Sector
Industry	Biotechnology Research
Country
Stage
Employee Count	18
Website	opnabio.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:OPNABIO

Opna Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue